Commentary · 21 Feb 2026
Conference abstractPublished 17 Sep 2018
Robust inhibition of lung cancer stem-like cell growth and tumorigenicity by triptonide via selectively attenuating Sonic Hedgehog-Gli1 signaling pathway
Soochow University, Peoples Republic of China
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Lung cancer is a leading lethal disease with the 5-year survival rate of the cancer patients only 16%. Inadequate potent anti-lung cancer drugs, particularly for suppression of lung cancer stem cells, appear to be a bottleneck in the treatment of the disease; hence, the effective anti-lung cancer drug is highly desired. In this study, we aim to explore new compound against lung cancer. Using human H1299 and A549 lung carcinoma cell lines as a model to screen and test the anti-lung cancerous compounds, we found that triptonide, a bioactive small molecule purified from the herb Tripterygium wilfordii Hook caused a marked suppression of cell proliferation and colony formation of lung cancer cells at very low concentrations of 5-10nM. More interestingly, triptonide robustly inhibited the lung cancer cell formation of tumorspheres, and reduced the stemness and tumorigenicity of the sphereforming cells, suggesting that triptonide is a new inhibitor of cancer stem-like cells. In vivo tumor xenograft assay in mice showed that administration of triptonide at the dose of 5mg/Kg markedly inhibited the tumor growth with low toxicity. Molecular mechanistic studies revealed that triptonide significantly decreased expression of the glioma-associated oncogene 1 (Gli1) at both mRNA and protein levels through repressing Gli1 gene promoter activity. Additionally, triptonide reduced the levels of cancer stem cell key signaling protein sonic hedgehog (Shh), but increased the amount of Ptch1 which is a protein binding to the smoothened protein (SMO) to diminish the Shh signal transduction, resulting in inhibiting an Shh-Gli1 signaling pathway in lung cancer cells. Together, our findings show that triptonide effectively inhibits lung cancer stem-like cell growth, stemness, and tumorigenicity, and support the notion that triptonide is a new inhibitor of cancer stem-like cells and Shh-Gli1 signaling inhibitor, and is a novel anti-lung cancer drug candidate for further developing effective lung cancer therapeutics.
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Cancer Science & Therapy.
Perspective · 21 Feb 2026
Finding Potential Passerini Adducts for Anticancer Drug Development
Perspective · 21 Feb 2026
Head and Neck Cutaneous Squamous Cell Carcinoma with Perineural Invasion
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalCancer Science & Therapy
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Quansheng Zhou”
- BylineArticles whose byline prints “Mengli Zhang”
- BylineArticles whose byline prints “Zhifei Cao”
